AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
DNA Base Excision Repair Inhibitor Drugs Enhance Chemotherapy.(Brief Article)
2001 NOV 15 - (NewsRx.com & NewsRx.net) -- Pangene Corporation announced that chemotherapy-resistant ovarian and colon cancer tumors treated with DNA base excision repair (BER) inhibitors drugs become more sensitive to DNA damaging chemotherapeutics.
A study entitled, "Base excision repair inhibitor drugs sensitize mammalian cells to iododeoxyuridine-induced cytotoxicity and radiosensitivity," was presented at the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Miami Beach, Florida, in October and was published in the conference proceedings.
"Several independent lines of evidence show the involvement of BER in the molecular mechanisms by which iododeoxyuridine (IdUrd) and certain other DNA base analogues cause cytotoxicity and radiosensitization of tumors," said Pietro Taverna, PhD, Pangene Corporation. "We ...
- Build, Fuel, and Drive Your Scientific Competitive Vehicle for the Advancement...
- Press release article from: M2 Presswire November 14, 2007 700+ words
...Advancement of New Protein Kinase Inhibitor Drugs in Oncology with the Help of This...belonging to 210 protein kinase inhibitor drugs. This report, The Drug Target Atlas...advancement of new protein kinase inhibitor drugs in oncology. In the report, the...
- New data announced on the effects of telomerase inhibitor drugs.
- Newspaper article from: Health & Medicine Week January 5, 2004 700+ words
...doses required to achieve efficacy. "We are very encouraged by this additional evidence for efficacy of our telomerase inhibitor drugs in treating multiple myeloma," said Thomas B. Okarma, PhD, MD, Geron's president and chief executive officer...
- Geron Announces New Data on the Effects of Its Telomerase Inhibitor Drugs on...
- Press release article from: Business Wire December 9, 2003 700+ words
...doses required to achieve efficacy. "We are very encouraged by this additional evidence for efficacy of our telomerase inhibitor drugs in treating multiple myeloma," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer...
- Extra label use of anti-influenza adamantine and neuraminidase inhibitor drugs...
- Newspaper article from: Food Chemical News March 27, 2006 700+ words
...71 FR 14374), FDA issued a final rule prohibiting the extra label use of anti-influenza adamantine and neuraminidase inhibitor drugs in chickens, turkeys and ducks. The agency said there is evidence that the extra label use of these drugs in these species...
- Medivir AB, of Huddinge, Sweden, said it entered a three-year R&D collaboration...
- Newspaper article from: BioWorld International December 18, 2002 700+ words
...Therapeutics Ltd., of Cambridge, UK, focused on the identification of novel protease targets and the discovery of protease inhibitor drugs. Medivir will supply its expertise in protease inhibitor drug discovery, which includes proprietary screening methods...
- ACE inhibitor drugs underused in heart failure patients.
- Magazine article from: Managed Care Weekly August 23, 2004 700+ words
2004 AUG 23 - (NewsRx.com & NewsRx.net) -- Almost a third of heart failure patients face an increased risk of death because they do not receive an angiotensin-converting enzyme (ACE) inhibitor, according to a new report. Overwhelming evidence accumulated during almost 20 years of clinical
- Study: ACE inhibitor drugs are underused.(angiotensin-converting enzyme)(Brief...
- Newspaper article from: HealthCare Benchmarks and Quality Improvement November 1, 2004 700+ words
Almost one-third of heart failure patients face an increased risk of death because they do not receive an angiotensin-converting enzyme (ACE) inhibitor, according to a report in the Aug. 3, 2004, rapid-access issue of Circulation: Journal of the American Heart Association. A review of data from the
- SGX and UroGene Collaborate to Develop Kinase Inhibitor Drugs to Treat...
- Press release article from: PR Newswire December 16, 2003 700+ words
SAN DIEGO and EVRY, France, Dec. 16 /PRNewswire/ -- Privately held biotechnology companies, SGX (Structural GenomiX, Inc.) and UroGene S.A., of France, today announced that they have formed a joint research and development collaboration for the discovery and clinical development of novel drugs for
- SGX and UroGene collaborate to develop kinase inhibitor drugs to treat...
- News wire article from: Asia Africa Intelligence Wire December 16, 2003 700+ words
(From Chemical Business NewsBase - Press Release) Structural GenomiX Inc (SGX) and UroGene SA, France, have formed a joint research and development collaboration for the discovery and clinical development of novel drugs for the treatment of urological cancers. Under the terms of the agreement, SGX
- Geron announces new data on the effects of its telomerase inhibitor drugs on...
- News wire article from: Asia Africa Intelligence Wire December 9, 2003 700+ words
(From Chemical Business NewsBase - Press Release) Geron Corp announced the presentation of additional positive data from studies of its two telomerase inhibitor drug candidates, GRN163 and GRN163L, in animal models of human multiple myeloma. The results were presented at the American Society of
Source: HighBeam Research, DNA Base Excision Repair Inhibitor Drugs Enhance Chemotherapy.(Brief...